share_log

Transcode Therapeutics | 8-K/A: Current report (Amendment)

Transcode Therapeutics | 8-K/A: Current report (Amendment)

Transcode Therapeutics | 8-K/A：重大事件(修正)
美股SEC公告 ·  2024/06/14 20:04

Moomoo AI 已提取核心信息

At Transcode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted against the proposed reverse stock split that would have allowed for a ratio between 1-for-2 and 1-for-40. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares.Shareholders approved most other proposals, including the election of four directors (Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet), the amendment to increase shares under the 2021 Stock Option and Incentive Plan by 3 million shares, and the appointment of WithumSmith+Brown as the independent auditor for FY2024.The Adjournment Proposal was approved with 1,289,670 votes in favor, though no corresponding motion was made to adjourn the meeting following the approval. The rejected reverse stock split proposal received 1,018,164 votes in favor versus 1,277,915 against.
At Transcode Therapeutics' 2024 Annual Meeting held on June 13, shareholders voted against the proposed reverse stock split that would have allowed for a ratio between 1-for-2 and 1-for-40. The meeting saw participation from 2,392,577 shares out of 6,108,053 eligible voting shares.Shareholders approved most other proposals, including the election of four directors (Philippe Calais, Thomas Fitzgerald, Erik Manting, and Magda Marquet), the amendment to increase shares under the 2021 Stock Option and Incentive Plan by 3 million shares, and the appointment of WithumSmith+Brown as the independent auditor for FY2024.The Adjournment Proposal was approved with 1,289,670 votes in favor, though no corresponding motion was made to adjourn the meeting following the approval. The rejected reverse stock split proposal received 1,018,164 votes in favor versus 1,277,915 against.
TransCode Therapeutics，Inc.向美国证券交易委员会提交了一份修正版8-K表格报告，以更正其2024年股东年会投票结果的错误。该修正解释了并非所有提案都获得股东批准的事实。在会议期间，四位董事候选人当选，股票计划修正提案和审计提案均获批准。然而，反向股票拆分提案未能通过，而休会提案在没有随后的休会动议的情况下获得批准。详细的投票结果被披露，包括每个提案的赞成票数、反对票数、弃权票数和代理人未投票的情况（如适用）。
TransCode Therapeutics，Inc.向美国证券交易委员会提交了一份修正版8-K表格报告，以更正其2024年股东年会投票结果的错误。该修正解释了并非所有提案都获得股东批准的事实。在会议期间，四位董事候选人当选，股票计划修正提案和审计提案均获批准。然而，反向股票拆分提案未能通过，而休会提案在没有随后的休会动议的情况下获得批准。详细的投票结果被披露，包括每个提案的赞成票数、反对票数、弃权票数和代理人未投票的情况（如适用）。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日